Is RGA a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for Reinsurance Group of America (RGA) rests on Financial Solutions and the Equitable block: The largest single addition to earnings power in recent years closed on July 31, 2025, when RGA completed a reinsurance transaction covering $32 billion of Equitable Holdings life liabilities, $18 billion of general account reserves and $14 billion of separate account reserves, with $1.5 billion of capital deployed at closing. The bear case rests on the clearest risk is the one the business exists to take. Analysts covering it publish targets from $250.00 to $325.00 against a $266.78 share price on November 20, 2026, so even the professionals disagree by 25% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

RGA key stats

At $266.78 on November 20, 2026, Reinsurance Group of America (RGA) has a market cap of $17.4B, a P/E of 10.3 on trailing earnings (8.7 on forward earnings) and a dividend yield of 1.47%.

Market cap
$17.4B
P/E (trailing)
10.3
P/E (forward)
8.7
EPS (trailing 12 months)
$25.82
Price to book
1.5
Dividend yield
1.47%
Beta
0.40

Market cap, P/E and yield are measured at the $266.78 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Reinsurance Group of America (RGA)?

The last two weeks for Reinsurance Group of America, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • RGA closed at $266.78 on November 20, 2026, down 3.0% over the past five trading days (from $275.15).
  • On November 19, 2026, UBS raised its target to $325.00 from $236.00 (Buy).
  • On November 12, 2026, Wells Fargo raised its target to $312.00 from $292.00 (Overweight).
  • On November 12, 2026, Evercore ISI Group raised its target to $285.00 from $280.00 (Outperform).

Reinsurance Group of America filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

RGA began as the reinsurance arm of General American Life, went public in 1993, and became fully independent when MetLife split off its majority stake in 2008. The company sells reinsurance to life and health insurers, which means it takes a share of claims risk that a primary carrier has already written. Reporting runs through four geographic segments, U.S. and Latin America, Canada, Europe Middle East and Africa, and Asia Pacific, and each one is split into two very different businesses. Traditional reinsurance covers individual and group life and health mortality and morbidity, usually on yearly renewable term treaties that generate steady premium for decades once written. Financial Solutions is the balance-sheet business: asset-intensive annuity and legacy life blocks, longevity swaps, pension risk transfer and capital-relief structures, where RGA takes on reserves and the assets backing them and earns an investment spread. Scale is substantial. Net premiums were $4.472 billion in the second quarter of 2026 and $9.067 billion for the first half, total assets stood at ~$167 billion at June 30, 2026, and the invested portfolio behind those liabilities is ~$145 billion. In fiscal 2025, U.S. and Latin America contributed roughly half of segment revenue, with Asia Pacific next at ~$5.1 billion. Two engines drive the numbers. The first is underwriting margin on mortality and longevity, which shows up as claims experience running better or worse than the assumptions priced into a treaty. Second quarter economic claims came in ~$31 million better than expected, and U.S. individual mortality has run about $70 million favorable year to date. The second engine is investment spread, where the portfolio core yield of 4.96% sits well below the 6.02% new money rate, so every maturity reinvested at current rates adds to income, and variable investment income of $166 million in the quarter came in at a 15% annualized return against a 7% plan for 2026. GAAP net income swings on items management strips out, including embedded derivatives on funds-withheld treaties, which is why the reported and adjusted numbers diverge: $7.01 of net income per diluted share in the quarter against $8.89 of adjusted operating income. As of November 20, 2026 the market pays ~10.4x trailing earnings and ~8.8x forward estimates for a company targeting 8% to 10% intermediate-term EPS growth and a 13% to 15% ROE, both of which it is running above today. The stock has rerated with those results. RGA beat consensus EPS in each of the last four reported quarters, most sharply in Q2 2026 ($8.89 adjusted against a ~$6.49 estimate) and Q3 2026 ($8.49 against ~$6.95). The third quarter, reported November 5, brought revenue of about $7.55 billion, up roughly 22% year over year, net income of about $456 million, and $736 million of pre-tax adjusted operating income. Economic claims ran ~$67 million better than expected, variable investment income again returned about 15% annualized, new money went to work at 6.31%, and four U.S. pension risk transfer deals added over $800 million of premium. Trailing adjusted operating ROE excluding notable items rose to 19.1%. The shares closed at $269.42 on November 20, 2026, up ~32% year to date and ~46% over one year, a little below a 52-week high of $277.15 set after the report. Market capitalization is ~$17.5 billion. UBS upgraded the stock to buy on November 19 with a $325 target, and the nine-analyst mean target is ~$298. Consensus calls for ~$7.30 of adjusted EPS in Q4 2026, ~$31.70 for full-year 2026 and ~$30.74 in 2027, about 3% lower.

The bull case: what would have to be true for $325.00

The most optimistic published target on RGA is $325.00, +21.8% from the $266.78 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Financial Solutions and the Equitable block

The largest single addition to earnings power in recent years closed on July 31, 2025, when RGA completed a reinsurance transaction covering $32 billion of Equitable Holdings life liabilities, $18 billion of general account reserves and $14 billion of separate account reserves, with $1.5 billion of capital deployed at closing. Management guided the deal to ~$70 million of pre-tax adjusted operating income in 2025, $160 million to $170 million in 2026, and roughly $200 million a year at maturity. The wider Financial Solutions book is now a major share of quarterly profit: in the second quarter of 2026 it produced $154 million of pre-tax adjusted operating income in U.S. and Latin America, $133 million in EMEA, $120 million in Asia Pacific and $18 million in Canada. Reported global Financial Solutions premiums grew ~85% year to date, a figure inflated by large single-premium transactions rather than organic run rate.

2. Reinvestment spread on a $145 billion portfolio

Asset-intensive reinsurance turned RGA into a large investor as well as an underwriter. Net investment income rose 10.3% year over year in the second quarter at an average yield of 5.33%, while the core portfolio yield was 4.96% and new money went to work at 6.02% for the quarter, up from 5.64% in the prior quarter. The gap between those two numbers is the arithmetic behind several years of income growth, because maturing older-vintage bonds roll into higher coupons without any new business being written. Variable investment income, mostly limited partnership and alternative equity marks, added $166 million at a 15% annualized rate against a 7% assumption for 2026 and a 10% to 12% long-run target. In the third quarter the new money rate rose again to 6.31% against an unchanged 4.96% core yield, and alternatives returned about 15% annualized (about 12% year to date), while impairments and allowance changes cost $71 million. Management expects full-year variable returns within the 10% to 12% long-run range. Quarters where alternatives undershoot plan will make the same line a drag.

3. Deliberate restraint in the Traditional book

Traditional premiums grew 2.2% on a reported basis in the second quarter and 0.9% in constant currency, growth management describes as the result of in-force management actions rather than lost competitiveness. Total year-to-date premiums rose 10.5% excluding pension risk transfer, so the slow line is specific to legacy mortality treaties being repriced or recaptured. Appetite stays narrow in universal life with secondary guarantees and in long-term care, two categories that have produced reserve charges across the industry. The trade-off is visible in results: a mortality book that grows slowly but delivered $31 million of favorable economic claims in the quarter, funding the capital that goes into Financial Solutions deals.

4. Capital deployment ahead of buybacks

RGA ended the second quarter with ~$2.2 billion of estimated excess capital and ~$2.7 billion of deployable capital against $7.2 billion of available liquidity. Roughly $500 million went into in-force transactions in the first half at returns management says met or exceeded targets, including $158 million in the second quarter alone. Shareholder distributions stayed modest by comparison at $111 million for the quarter, $61 million in dividends and $50 million of repurchases, with the quarterly dividend lifted 5.4% to $0.98 per share. The Ruby Re sidecar brings third-party capital alongside RGA's own, which lets the company write larger blocks without funding every dollar off its own balance sheet. By September 30 excess capital had fallen to about $1.8 billion, after RGA retired $400 million of senior securities and deployed another $119 million into in-force transactions, and Ruby Re's third-party capital was fully deployed. Third-quarter shareholder returns rose to $139 million ($75 million of buybacks and $64 million of dividends), bringing year-to-date repurchases to $175 million. Priorities are stated plainly: deals first, capital return with what is left.

The bear case: what would have to be true for $250.00

The most pessimistic published target is $250.00, -6.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Reinsurance Group of America is worth if the risks below bite instead of the drivers above.

The clearest risk is the one the business exists to take. Mortality and morbidity experience can move against a book of treaties written years earlier, as it did in 2020 and 2021 when pandemic claims pushed RGA to losses, and the same sensitivity now runs in both directions because longevity exposure in pension risk transfer and annuity blocks pays off when people die earlier than assumed. A single large block priced on wrong assumptions is difficult to unwind. Credit risk has grown alongside the asset-intensive strategy: a ~$145 billion portfolio backing long-dated liabilities carries corporate credit, commercial mortgage and private-asset exposure, and a downgrade cycle would hit capital before it hit income. Accounting adds noise that is easy to mistake for economics. Embedded derivatives on funds-withheld treaties and other adjustments put a $1.88 per share gap between second quarter net income of $7.01 and adjusted operating income of $8.89, and book value per share swings with AOCI, which stood at $209.73 including AOCI versus $173.77 excluding it at June 30, 2026. Management flagged ~$0.83 per share of one-time items in the quarter that it says are not indicative of trend, so extrapolating the record print overstates the base. Competition for asset-intensive blocks comes from private-equity-backed platforms with cheaper capital, which compresses returns on exactly the deals driving growth. Regulatory and tax changes matter more than for most financials: potential Hong Kong tax law changes were called out for Asia Pacific, and Bermuda and U.S. capital rules shape how blocks are structured. After a ~46% one-year gain, the shares also carry less valuation cushion than they did, and consensus for 2027 EPS (~$30.74) sits about 3% below 2026 (~$31.70), so a quarter that falls short of the elevated run rate could weigh on the multiple. Ratings are load-bearing, since cedents choose reinsurers partly on financial strength. Third-quarter results again included favorable items: claims, variable investment income, in-force actions and other items together ran $117 million better than expectations. With ~$5.3 billion of debt and only ~65 million shares outstanding, both leverage and per-share results amplify whatever happens underneath.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RGA already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on RGA

9 analysts cover RGA, with an average target of $297.78 (+11.6% against $266.78) and a split of 8 buy, 1 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RGA forecast and price target page.

How is RGA valued?

Market cap, P/E and dividend yield at today's price are in the RGA key stats above. The business figures below come from Reinsurance Group of America's reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$27.3 billion for the twelve months to September 30, 2026, with third-quarter revenue of ~$7.55 billion up ~21.7% year over year, versus $23.70 billion in fiscal 2025, $22.11 billion in 2024 and $18.57 billion in 2023. The line combines net premiums with net investment income and fee income, so growth reflects both new reinsurance treaties (including over $800 million of U.S. pension risk transfer premium in Q3) and the yield earned on assets backing reserves, not unit sales. Reported in U.S. dollars, with material Canadian dollar, sterling, euro and yen exposure translated in.
  • Earnings (TTM): ~$1.71 billion of net income and ~$25.82 of diluted EPS for the twelve months to September 30, 2026, against $1.18 billion and $17.69 in fiscal 2025 and $717 million and $10.73 in 2024. Third quarter 2026 net income was ~$456 million, and pre-tax adjusted operating income was $736 million, or $8.49 of adjusted operating EPS after a 24.1% tax rate. Adjusted EPS has beaten consensus for four straight quarters: $7.75 vs ~$5.75 in Q4 2025, $6.97 vs ~$6.01 in Q1 2026, $8.89 vs ~$6.49 in Q2 2026 and $8.49 vs ~$6.95 in Q3 2026. Consensus for Q4 2026 is ~$7.30.
  • Premiums and segment income (Q2 2026): Net premiums of $4.472 billion in the quarter and $9.067 billion through the first half, up 11.0% on a reported basis and 9.3% in constant currency excluding pension risk transfer (through September, total premiums excluding PRT were up 8.9%). Pre-tax adjusted operating income by segment in Q2: U.S. and Latin America Traditional $165 million and Financial Solutions $154 million, Asia Pacific Traditional $129 million and Financial Solutions $120 million, EMEA Traditional $39 million and Financial Solutions $133 million, Canada Traditional $38 million and Financial Solutions $18 million, with a $35 million loss in Corporate and Other. Segment reporting simplifies to four segments from Q4 2026.
  • Returns and book value: Trailing twelve-month adjusted operating ROE of 19.1% excluding AOCI and notable items at September 30, 2026, up from 18.4% at June 30 and above the 13% to 15% intermediate-term target. Book value per share excluding AOCI and the B36 funds-withheld embedded derivative effect was $178.59, compounding at 10.2% a year since the start of 2021 (it was $174.11 at June 30, when book value including AOCI was $209.73).
  • Capital, liquidity and distributions: ~$1.8 billion of estimated excess capital at September 30, 2026, down from ~$2.2 billion at June 30 after a $400 million senior security retirement, against ~$5.3 billion of total debt and ~$5.0 billion of cash and equivalents. Capital deployed into in-force transactions was $119 million in Q3, and Ruby Re third-party capital is fully deployed. Shareholder returns totaled $139 million in Q3, split $75 million of buybacks and $64 million of dividends, with $175 million repurchased year to date at a quarterly dividend of $0.98 per share.
  • Market pricing: ~$269.42 per share on November 20, 2026 for a market capitalization of ~$17.5 billion, near the top of a 52-week range of $184.78 to $277.15. The shares are up ~32% year to date and ~46% over one year, and change hands at ~10.4x trailing earnings, ~8.8x forward estimates and ~1.5x book excluding AOCI. The dividend of $3.92 annualized yields ~1.5%. EV/EBITDA is not a standard lens for life reinsurers, since debt and investment income are operating inputs rather than financing adjustments. The analyst consensus rating is buy, with a mean target near ~$298 across nine analysts; UBS moved to buy with a $325 target on November 19, 2026.

As of November 2026: A trailing P/E near 10 and ~1.5x book excluding AOCI on a 19% adjusted operating ROE still reflects a discount for how the returns were earned, even after the shares rallied ~46% over a year. Investors have seen life reinsurers report strong mortality quarters and then take reserve charges, and the asset-intensive growth of the past three years adds credit exposure that only reveals itself in a downturn. The forward multiple below the trailing one, and 2027 consensus EPS of about $30.74 sitting slightly under the ~$31.70 expected for 2026, show the market expecting some normalization from this year's print rather than continued acceleration.

How do you decide if RGA is a buy?

Whether RGA is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold RGA indirectly through an index or sector ETF before adding more.

What would change your mind on RGA

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Financial Solutions and the Equitable block stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: the clearest risk is the one the business exists to take fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RGA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RGA against your real portfolio and see your actual exposure before deciding.

Your questions about Reinsurance Group of America

Ask Walnut's AI anything about RGA and see how it fits what you own.

FAQ

Is RGA a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Financial Solutions and the Equitable block, with revenue (ttm) at ~$27.3 billion for the twelve months to September 30, 2026, with third-quarter revenue of ~$7.55 billion up ~21.7% year over year, versus $23.70 billion in fiscal 2025, $22.11 billion in 2024 and $18.57 billion in 2023. The line combines net premiums with net investment income and fee income, so growth reflects both new reinsurance treaties (including over $800 million of U.S. pension risk transfer premium in Q3) and the yield earned on assets backing reserves, not unit sales. Reported in U.S. dollars, with material Canadian dollar, sterling, euro and yen exposure translated in.. The bear case rests on the clearest risk is the one the business exists to take. Analysts covering it are spread from $250.00 to $325.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell RGA?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The clearest risk is the one the business exists to take. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $250.00, -6.3% from the $266.78 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for RGA?

+

Financial Solutions and the Equitable block. The largest single addition to earnings power in recent years closed on July 31, 2025, when RGA completed a reinsurance transaction covering $32 billion of Equitable Holdings life liabilities, $18 billion of general account reserves and $14 billion of separate account reserves, with $1.5 billion of capital deployed at closing. The most optimistic analyst target on RGA is $325.00, +21.8% from the $266.78 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for RGA?

+

The clearest risk is the one the business exists to take. Mortality and morbidity experience can move against a book of treaties written years earlier, as it did in 2020 and 2021 when pandemic claims pushed RGA to losses, and the same sensitivity now runs in both directions because longevity exposure in pension risk transfer and annuity blocks pays off when people die earlier than assumed. A single large block priced on wrong assumptions is difficult to unwind. Credit risk has grown alongside the asset-intensive strategy: a ~$145 billion portfolio backing long-dated liabilities carries corporate credit, commercial mortgage and private-asset exposure, and a downgrade cycle would hit capital before it hit income. Accounting adds noise that is easy to mistake for economics. Embedded derivatives on funds-withheld treaties and other adjustments put a $1.88 per share gap between second quarter net income of $7.01 and adjusted operating income of $8.89, and book value per share swings with AOCI, which stood at $209.73 including AOCI versus $173.77 excluding it at June 30, 2026. Management flagged ~$0.83 per share of one-time items in the quarter that it says are not indicative of trend, so extrapolating the record print overstates the base. Competition for asset-intensive blocks comes from private-equity-backed platforms with cheaper capital, which compresses returns on exactly the deals driving growth. Regulatory and tax changes matter more than for most financials: potential Hong Kong tax law changes were called out for Asia Pacific, and Bermuda and U.S. capital rules shape how blocks are structured. After a ~46% one-year gain, the shares also carry less valuation cushion than they did, and consensus for 2027 EPS (~$30.74) sits about 3% below 2026 (~$31.70), so a quarter that falls short of the elevated run rate could weigh on the multiple. Ratings are load-bearing, since cedents choose reinsurers partly on financial strength. Third-quarter results again included favorable items: claims, variable investment income, in-force actions and other items together ran $117 million better than expectations. With ~$5.3 billion of debt and only ~65 million shares outstanding, both leverage and per-share results amplify whatever happens underneath. The most pessimistic published target is $250.00, -6.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does Reinsurance Group of America do?

+

Reinsurance Group of America is one of the largest life and health reinsurers, assuming mortality and morbidity risk from primary insurers worldwide.

What would have to change for RGA to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Financial Solutions and the Equitable block) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (the clearest risk is the one the business exists to take) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does Reinsurance Group of America (RGA) do?

+

RGA is a life and health reinsurer. When an insurance company writes a life policy, a disability policy or a group health plan, it can pass some of that claims risk to RGA in exchange for a share of the premium. The company operates in roughly 30 countries and reports through four geographic segments: U.S. and Latin America, Canada, Europe Middle East and Africa, and Asia Pacific. Each segment contains a Traditional business, which takes mortality and morbidity risk, and a Financial Solutions business, which reinsures asset-intensive blocks such as annuities, legacy life portfolios, longevity swaps and pension risk transfer. Net premiums ran $4.472 billion in the second quarter of 2026, with total assets of ~$167 billion at June 30, 2026.

How does RGA make money?

+

Two sources, roughly balanced. Underwriting margin comes from pricing mortality and longevity risk correctly, so profit appears when claims run below the assumptions built into a treaty. In the second quarter of 2026, economic claims were ~$31 million better than expected and U.S. individual mortality has been ~$70 million favorable year to date. Investment spread comes from the ~$145 billion portfolio backing reserves: the core book yield is 4.96% while new money is being invested at 6.02%, so reinvestment lifts income without new business. Variable investment income from alternatives added $166 million in the quarter. Fee income from capital-relief structures makes up a smaller third slice. Total pre-tax adjusted operating income was $761 million in the quarter.

Is RGA a good dividend stock?

+

RGA pays a quarterly dividend of $0.98 per share after a 5.4% increase, or $3.92 annualized, which works out to a yield of ~1.5% at ~$269.42 per share (November 20, 2026). Coverage is not the constraint: $61 million of dividends in the second quarter sat against $586 million of adjusted operating income, a payout ratio in the mid teens. The low yield reflects a deliberate choice, since management directs capital toward in-force reinsurance transactions first, with close to $500 million deployed in the first half of 2026 against $50 million of buybacks in the second quarter and $75 million in the third. Income-focused investors get a growing but small dividend; the return case rests mainly on book value compounding at ~10% a year.

Walnut is informational, not investment advice, and gives no verdict on RGA. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks